Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-90006 · 1 trial · 1 indication
Number of participants with adverse events
| Arm | Type | Description |
|---|---|---|
| CC-90006; Dose level 1 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 2 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 3 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| CC-90006; Dose level 4 | EXPERIMENTAL | CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29. |
| Placebo | PLACEBO_COMPARATOR | Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29. |
| Name | Type | Description |
|---|---|---|
| CC-90006 | DRUG | CC-90006 |
| Placebo | OTHER | Placebo |
Inclusion Criteria: The following is a summary of the inclusion criteria: 1. Males or non-pregnant females between the ages of 18 and 60 years (inclusive) at the time of signing the ICF, and be willing to adhere to the requirements of contraception use throughout the study. 1. Female subjects ...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
CC-90006 is an investigational small molecule developed by Bristol-Myers Squibb Company (ticker: BMY) for the treatment of psoriasis, a dermatological condition. It has been studied in a Phase 1 clinical trial in adults with mild to moderate plaque-type psoriasis. It is not an approved therapy and remains in clinical development.
CC-90006 was studied for the treatment of mild to moderate plaque-type psoriasis in adults aged 18 years and older. The single Phase 1 trial enrolled 34 participants with this condition in the United States and Canada. Because the program is at the Phase 1 stage, CC-90006 is investigational and has no approved use.
CC-90006 is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored the Phase 1 study of the compound in patients with mild to moderate plaque-type psoriasis. Bristol-Myers Squibb is the developer associated with this asset.
CC-90006 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized, double-blind, and placebo-controlled, enrolling 34 participants. CC-90006 is investigational and has not been approved for any indication.
CC-90006 has been evaluated in one clinical trial, NCT03337022, titled a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CC-90006 in subjects with mild to moderate plaque-type psoriasis. The Phase 1 trial is completed, enrolled 34 participants, and was conducted in the United States and Canada.
Yes. The Phase 1 trial of CC-90006, NCT03337022, was randomized, double-blind, and placebo-controlled. It enrolled 34 adults with mild to moderate plaque-type psoriasis across sites in the United States and Canada. The study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity, and it is now completed.